Valuation: Geron Corporation

Market Cap 911M 800M 744M 683M 1.28B 87.73B 1.3B 8.84B 3.45B 43.13B 3.42B 3.35B 149B P/E 2026 *
-88.8x
P/E 2027 * 15.8x
Enterprise Value 890M 782M 727M 667M 1.25B 85.71B 1.27B 8.63B 3.37B 42.14B 3.34B 3.27B 146B EV / Sales 2026 *
3.8x
EV / Sales 2027 * 2.17x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-2.07%
1 week-1.39%
Current month+10.94%
1 month+3.65%
3 months-5.33%
6 months+2.90%
Current year+7.58%
1 week 1.39
Extreme 1.3901
1.48
1 month 1.26
Extreme 1.26
1.62
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 07/08/2025
Director of Finance/CFO 59 25/09/2023
Chief Tech/Sci/R&D Officer - 01/10/2025
Director TitleAgeSince
Director/Board Member 76 21/05/2010
Director/Board Member 72 28/09/2012
Director/Board Member 55 26/03/2019
Date Insider Type Main position Quantity % Market Cap.
30/6/26 Free

Director

6,103 0.0010%
20/5/26 Free

Director

220,000 0.0343%
20/5/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-2.07%-1.39%+12.70%-52.67% 911M
+0.93%+6.97%+59.60%+68.35% 57.28B
-1.92%+6.03%+40.64%+83.42% 54.99B
-0.46%-1.29%+2.86%+428.78% 23.18B
-2.97%-2.35%-22.53%-16.40% 22.59B
-0.36%+5.73%+24.13%-6.24% 20.46B
-1.34%+0.51%+26.03%-29.41% 17.56B
-1.44%+5.67%+38.77%+504.71% 15.67B
-1.30%-5.02%+170.77%+291.37% 14.46B
-0.50%-0.98%+21.43%+180.07% 13.92B
Average -1.14%+1.01%+37.44%+145.20% 24.1B
Weighted average by Cap. -0.88%+2.08%+39.60%+132.79%

Financials

2026 *2027 *
Net sales 234M 206M 191M 176M 330M 22.56B 335M 2.27B 888M 11.09B 879M 860M 38.34B 342M 301M 280M 257M 482M 32.97B 490M 3.32B 1.3B 16.21B 1.29B 1.26B 56.04B
Net income -10.96M -9.63M -8.95M -8.22M -15.44M -1.06B -15.68M -106M -41.54M -519M -41.15M -40.26M -1.79B 65.62M 57.63M 53.6M 49.18M 92.41M 6.32B 93.83M 636M 249M 3.11B 246M 241M 10.74B
Net Debt -20.97M -18.42M -17.13M -15.72M -29.53M -2.02B -29.99M -203M -79.46M -993M -78.72M -77.02M -3.43B -169M -148M -138M -127M -238M -16.28B -242M -1.64B -640M -8B -634M -621M -27.66B
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
24/07/26 US$1.420 -2.07% 3,292,732
23/07/26 US$1.450 +2.84% 4,264,753
22/07/26 US$1.410 -2.08% 5,693,370
21/07/26 US$1.440 0.00% 5,143,963
20/07/26 US$1.440 0.00% 5,209,660
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.420USD
Average target price
4.250USD
Spread / Average Target
+199.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock